Patents Assigned to JESALIS PHARMA GMBH
  • Patent number: 9211485
    Abstract: A method and device for producing crystalline active ingredient particles. The active ingredient is crystallized from a supersaturated solution on the surface of particles of the active ingredient. A suspension of active ingredient particles is subjected to wet grinding in a supersaturated solution of the active ingredient in a first module. At least a part of the suspension is fed from the first module into the second module where it is cooled and simultaneously subjected to ultrasound. The suspension is fed back into the first module after cooling and being subjected to ultrasound. Active ingredient solution and optionally antisolvent are added to the suspension and active ingredient particles and liquid phase are extracted. A relative supersaturation of the active ingredient in the liquid phase of the suspension, relative to the entire liquid phase, is ?90%, and the extracted active ingredient particles comprise a mean particle size of 10-500 ?m.
    Type: Grant
    Filed: March 30, 2011
    Date of Patent: December 15, 2015
    Assignee: Jesalis Pharma GmbH
    Inventors: Detlef Grawe, Sabine Gliesing
  • Patent number: 9173843
    Abstract: A method for producing highly crystalline and stable microparticles of an active substance with a very narrow size distribution. The microparticles being crystallized out of a suspension made of primary particles of the active substance, a solution of the active substance, a non-solvent for the active substance and inert formed pieces. The resulting microparticles hare are highly stable largely independent of the physiochemical properties of the active substance and can be especially suitable for fast release dosage forms of pharmaceuticals.
    Type: Grant
    Filed: June 30, 2009
    Date of Patent: November 3, 2015
    Assignee: Jesalis Pharma GMBH
    Inventors: Detlef Grawe, Sabine Gliesing, Robert Eilers
  • Publication number: 20130040141
    Abstract: A method and device for producing crystalline active ingredient particles. The active ingredient is crystallized from a supersaturated solution on the surface of particles of the active ingredient. A suspension of active ingredient particles is subjected to wet grinding in a supersaturated solution of the active ingredient in a first module. At least a part of the suspension is fed from the first module into the second module where it is cooled and simultaneously subjected to ultrasound. The suspension is fed back into the first module after cooling and being subjected to ultrasound. Active ingredient solution and optionally antisolvent are added to the suspension and active ingredient particles and liquid phase are extracted. A relative supersaturation of the active ingredient in the liquid phase of the suspension, relative to the entire liquid phase, is ?90%, and the extracted active ingredient particles comprise a mean particle size of 10-500 ?m.
    Type: Application
    Filed: March 30, 2011
    Publication date: February 14, 2013
    Applicant: JESALIS PHARMA GMBH
    Inventors: Detlef Grawe, Sabine Gliesing
  • Publication number: 20110144071
    Abstract: A method for producing highly crystalline and stable microparticles of an active substance with a very narrow size distribution. The microparticles being crystallized out of a suspension made of primary particles of the active substance, a solution of the active substance, a non-solvent for the active substance and inert formed pieces. The resulting microparticles hare highly stable largely independent of the physiochemical properties of the active substance and can be especially suitable for fast release dosage forms of pharmaceuticals.
    Type: Application
    Filed: June 30, 2009
    Publication date: June 16, 2011
    Applicant: JESALIS PHARMA GMBH
    Inventors: Detlef Grawe, Sabine Gliesing, Robert Eilers